---
title: "Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Economic information and modeling report. Covers Cost-effectiveness evidence. 30 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics/cost-effectiveness"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary

- Model structure (NICE TA1199, nirogacestat): a semi-Markov model comparing nirogacestat with best supportive care, to which the EAG added chemotherapy; 28-day cycles with a half-cycle correction to drug costs over a lifetime horizon; 5 health states (stable disease, complete response, partial response, progressed disease, death). Comparators were combined as a basket weighted by confidential SpringWorks 2024 market research, and the committee assumed that chemotherapy was equivalent to nirogacestat for PFS.
- Utilities: De-Fi did not collect EQ-5D data. The company base case used soft-tissue sarcoma values from Shingler et al. 2013 (0.263 for progressed disease); the committee preferred EQ-5D values from Reichardt et al. 2012 (0.560 for progressed disease). The De-Fi QLQ-C30 data mapped to EQ-5D are confidential.
- Treatment duration: the committee assumed that 5% of people continue treatment into year 3 and that 10% of those in complete response, partial response, or stable disease are retreated at year 3 for up to 1 year. The NICE resource impact template assumes 1 year of treatment, the G-BA assumes one year (365 days), and Immunome states that patients may receive “~1.5–2 years of treatment”.
- Prices: nirogacestat U.S. WAC of $7,746.58 per package (01/05/2026), England list price of £15,189.04 per 56 pack of 150 mg tablets with a confidential discount, and German annual treatment cost of €260,760.82 per patient; sorafenib at $309/day at Medicare Part D rates (Johns et al. 2023).
- Patient numbers: SpringWorks estimates of 5,500 to 7,000 U.S. patients actively managed per year (market research) and approximately 11,000 receiving physician care (ICD-10 claims); Immunome's “10-11k Actively Managed Patients (US)”; 223 people eligible in England, derived from a soft-tissue sarcoma prevalence of 5.55 per 10,000 adults, 3% of which are desmoid tumors, an incidence of 4 per 1,000,000 adults, and 40% progressing; and approximately 350 to 630 patients in Germany.
- Other analyses: a SpringWorks-supported analysis of nirogacestat in DeFi (Malaviya et al. 2025) weighted health states with fixed utilities of 1.0, 0.5, and 0.5 over 20.6 months and reported a gain of 71.60 days versus placebo; it included no patient-reported utility data.
- No budget impact model of varegacestat was found: every heading of the budget impact model section of this report reads No evidence found.

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion); [NICE TA1199 information about nirogacestat (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/2-Information-about-nirogacestat); [NICE TA1199 resource impact summary report (2026)](https://www.nice.org.uk/guidance/ta1199/resources/resource-impact-summary-report-17421211693/chapter/Resource-impact-summary-report); [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf); [G-BA justification to the resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/40-1465-12520/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_TrG_EN.pdf); [SpringWorks Connecticut OGSIVEO price disclosure (2026)](https://springworkstx.com/wp-content/uploads/2024/06/CT-Price-Disclosure-Form-2024-v2.pdf); [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf); [Malaviya et al. (2025)](https://springworkstx.com/wp-content/uploads/2025/11/Malaviya_ISPOR-EU_2025_Q-TWiST_POS.pdf); [Johns et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35112974/)

<a id="topic-4.1-2"></a>

#### NICE TA1199 recommendation of nirogacestat under a commercial arrangement

> “Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults. Nirogacestat can only be used if the company provides it according to the commercial arrangement.”
> “There is enough evidence to show that nirogacestat provides benefits and value for money, so it can be used routinely across the NHS in this population.”
> “Nirogacestat has not been directly compared with chemotherapy in a clinical trial. Indirect comparisons suggest that nirogacestat is likely to work as well as chemotherapy, but this is uncertain.”
> “The cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, nirogacestat can be used.”

Source: [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation)

<a id="topic-4.1-3"></a>

#### NICE TA1199 list price and confidential discount for nirogacestat

> “The anticipated list price is £15,189.04 per 56 pack of 150‑mg tablets (company submission).”
> “The company has a commercial arrangement. This makes nirogacestat available to the NHS with a discount. The size of the discount is commercial in confidence.”

Source: [NICE TA1199 information about nirogacestat (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/2-Information-about-nirogacestat)

<a id="topic-4.1-4"></a>

#### NICE TA1199 economic model structure: semi-Markov model with 28-day cycles, a lifetime horizon, and 5 health states

> “The company submitted a semi-Markov model comparing nirogacestat with 'best supportive care' for treating progressing desmoid tumours that needed systemic treatment.”
> “The EAG updated the model to also include chemotherapy as a comparator for its base case, using evidence from the NMA (see section 3.5).”
> “The model applied 28‑day cycles, with a half-cycle correction to drug costs, over a lifetime horizon.”
> “The model contained 5 health states:”
> “stable disease”
> “complete response”
> “partial response”
> “progressed disease”
> “death.”
> “The health states were used in 2 different phases – during and after treatment, between which the structure and health-state interactions differed.”
> “The committee concluded that the overall structure of the model was suitable for decision making. The committee preferred to apply higher resource-use values from the EAG base case, because this better reflected clinical practice.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-4.1-5"></a>

#### NICE TA1199 comparators: best supportive care and chemotherapy, combined as a basket comparator

> “They thought that off-label chemotherapy would be used in about 30% to 50% of cases, particularly for sporadic tumours (see section 3.2).”
> “So, the committee concluded that 'best supportive care' (symptom management) and chemotherapy were the 2 relevant comparators in this evaluation.”
> “The basket comparator reflected the estimated mix of treatments that nirogacestat is expected to displace in NHS clinical practice, with the proportions of people having chemotherapy and best supportive care adding up to 100%.”
> “Incremental costs and quality-adjusted life years (QALYs) for chemotherapy and best supportive care were weighted according to their estimated use in clinical practice and combined to generate a blended ICER. This was based on UK usage data from a market research study done by SpringWorks Therapeutics in 2024.”
> “The company considered both the SpringWorks Therapeutics 2024 market research study and the ongoing ATU study to be confidential, so the estimates of treatment use cannot be reported here.”
> “Despite the uncertainty associated with estimating treatment proportions, it concluded that the proportions of best supportive care and chemotherapy proposed by the company were appropriate for decision making.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-4.1-6"></a>

#### NICE TA1199 indirect comparison assumptions for objective response and progression-free survival

> “So, the committee preferred to use the results of the NMA without Xu et al. for ORR.”
> “The committee noted the significant uncertainty in the evidence and the lack of demonstrable difference in effect between nirogacestat and chemotherapy. Because of this, the committee preferred to assume that for PFS chemotherapy was equivalent to nirogacestat.”
> “The EAG noted that this had a significant impact on the cost-effectiveness estimates.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-4.1-7"></a>

#### NICE TA1199 utility values: soft-tissue sarcoma proxies in the absence of EQ-5D data from De-Fi

> “Although the De‑Fi trial did not collect EQ-5D data, it did collect quality-of-life data using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.”
> “The utility values in the company base case were instead informed by published utility values from people with soft-tissue sarcoma (Shingler et al. 2013).”
> “The EAG stated that the utility value for progressed disease in the company base case was implausibly low for people with desmoid tumours (0.263). It explained that Shingler et al. was a time-trade-off study, which does not align with the NICE reference case.”
> “But, because this data was not provided, the EAG preferred to use utility values based on EQ-5D data from a clinical trial of people with soft-tissue sarcoma (Reichardt et al. 2012). This resulted in a utility value of 0.560 for progressed disease.”
> “At the second committee meeting, the company presented the EORTC QLQ-C30 quality-of-life data from De‑Fi, mapped to EQ-5D using the method from Young et al. (2015). These utilities are considered confidential by the company and so cannot be reported here.”
> “The committee noted that although there was uncertainty with using soft-tissue sarcoma as a proxy, it was reasonable in this instance because no other reliable utility evidence for desmoid tumours was available.”
> “So, it concluded that the utilities from the Reichardt et al. study were the most appropriate proxy utilities available.”
> “The committee concluded that pain would be reflected in the proxy soft-tissue sarcoma utility values but acknowledged that using a proxy carries a level of uncertainty.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-4.1-8"></a>

#### NICE TA1199 treatment duration, discontinuation, and retreatment assumptions

> “In its base case, the company assumed that everyone who has nirogacestat would stop treatment after 2 years.”
> “The company highlighted that based on data from its compassionate use programme (up to April 2025), less than 1% of people having nirogacestat continue treatment beyond year 2.”
> “A clinical expert at the meeting said that their NHS trust had extensive experience of using nirogacestat through the trial and through compassionate access. They explained that people in their practice usually stop nirogacestat after about 1 year, very few would continue beyond year 2 and the number of people needing retreatment is low.”
> “Based on this and in line with the company base case, the committee preferred to assume that:”
> “5% of people would continue treatment into year 3, and”
> “10% of people in the complete response, partial response and stable disease health states would have retreatment at year 3 for up to 1 year.”
> “The EAG preferred to model discontinuation to reflect De‑Fi.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-4.1-9"></a>

#### NICE TA1199 modeling of ovarian dysfunction

> “So, the EAG preferred to model ovarian dysfunction as a one-off event that occurred at the start of the model for a specific longer duration, based on De‑Fi.”
> “At the second committee meeting, the company updated its base case with the proportion of people with resolved ovarian dysfunction based on De‑Fi. It applied ovarian dysfunction as a one-off event to align with the EAG's base case. Unresolved ovarian dysfunction was assumed to continue through the treatment period and for 2.5 months after stopping treatment.”
> “It added that the changes in the model had a modest impact on the cost-effectiveness estimates.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-4.1-10"></a>

#### NICE TA1199 acceptable ICER and confidential cost-effectiveness estimates

> “NICE's technology appraisal and highly specialised technologies guidance manual notes that, above a most plausible ICER of £25,000 per QALY gained, judgements about the acceptability of a technology as an effective use of NHS resources will take into account the degree of certainty around the ICER.”
> “The company weighed up the uncertainty in the evidence, the unmet need, and the uncaptured benefits. It concluded that, based on the current evidence submitted, an acceptable ICER would be around £35,000 per QALY gained.”
> “After considering the uncertainty, the committee concluded that the cost-effectiveness estimates based on its preferred assumptions were within the range considered an acceptable use of NHS resources. The exact cost-effectiveness estimates cannot be reported here because of confidential discounts.”
> “The clinical expert also explained that people with desmoid tumours, particularly intra-abdominal tumours, may need stomas, ureteric stents and home intravenous nutrition. The need for these may be reduced if nirogacestat was available.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-4.1-11"></a>

#### NICE TA1199 resource impact: eligible population and uptake of nirogacestat in England

| Eligible population and uptake | Number of people eligible | Uptake for nirogacestat (%) | Number of people starting treatment with nirogacestat each year |
| --- | --- | --- | --- |
| “Current practice” | “223” | “0” | “0” |
| “Year 1” | “223” | “50” | “112” |
| “Year 2” | “195” | “60” | “117” |
| “Year 3” | “166” | “75” | “125” |

Source: [NICE TA1199 resource impact summary report (2026)](https://www.nice.org.uk/guidance/ta1199/resources/resource-impact-summary-report-17421211693/chapter/Resource-impact-summary-report)

<a id="topic-4.1-12"></a>

#### NICE TA1199 resource impact: epidemiological assumptions for the eligible population

> “The estimated prevalence of soft-tissue sarcoma is 5.55 per 10,000 adults (see the NDRS webpage on cancer prevalence).”
> “3% of people with soft-tissue sarcoma are estimated to have desmoid tumours (Borghi and Gronchi 2023).”
> “The estimated incidence of desmoid tumours is 4 per 1,000,000 adults (Bektas et al. 2023).”
> “40% of people with desmoid tumours in the in-year incidence population are expected to progress, requiring systemic treatment (Bektas et al. 2023).”
> “Clinical experts estimate that 25% of people who have not progressed will progress in later years; this is applied to the prevalent population not previously treated minus the incidence population.”

Source: [NICE TA1199 resource impact summary report (2026)](https://www.nice.org.uk/guidance/ta1199/resources/resource-impact-summary-report-17421211693/chapter/Resource-impact-summary-report)

<a id="topic-4.1-13"></a>

#### NICE TA1199 resource impact: treatment duration and capacity assumptions

> “A 1‑year treatment duration was estimated for nirogacestat, reflecting clinical expert opinion. In the resource impact template, users have the option to input additional cycles in year 2 if treatment duration is expected to exceed 1 year.”
> “Users can input the confidential price of nirogacestat and amend other variables in the resource impact template.”
> “Nirogacestat is administered orally, so there may be a capacity impact due to the additional oral administrations. If nirogacestat is administered via a homecare service, no additional administrations are expected.”

Source: [NICE TA1199 resource impact summary report (2026)](https://www.nice.org.uk/guidance/ta1199/resources/resource-impact-summary-report-17421211693/chapter/Resource-impact-summary-report)

<a id="topic-4.1-14"></a>

#### G-BA added benefit rating and number of patients eligible for nirogacestat in Germany

> “Adults with progressing desmoid tumours who require systemic treatment”
> “Extent of the additional benefit and significance of the evidence of nirogacestat:”
> “Hint for a minor additional benefit”
> “2. Number of patients or demarcation of patient groups eligible for treatment”
> “Approx. 350 to 630 patients”

Source: [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf)

<a id="topic-4.1-15"></a>

#### G-BA annual treatment costs of nirogacestat in Germany

> “Annual treatment costs/ patient”
> “Nirogacestat”
> “260,760.82”
> “Costs after deduction of statutory rebates (LAUER-TAXE® as last revised: 1 February 2026)”
> “Costs for additionally required SHI services: not applicable”

Source: [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf)

<a id="topic-4.1-16"></a>

#### G-BA basis for treatment costs and patient numbers: pack price, consumption, and uncertainty

> “The G-BA takes into account the patient numbers stated in the pharmaceutical company's dossier, which are, however, subject to uncertainty overall. There were methodological limitations and uncertainty regarding the percentages of desmoid tumours, which also relate exclusively to inpatients, under ICD-10 code D48.1. Furthermore, patients who had been ill for more than 5 years were not considered.”
> “If no maximum treatment duration is specified in the product information, the treatment duration is assumed to be one year (365 days), even if the actual treatment duration is different from patient to patient and/or is shorter on average.”
> “The annual treatment costs shown refer to the first year of treatment.”
> “730 x 300 mg”
> “Nirogacestat 150 mg”
> “56 FCT”
> “€ 21,213.56”
> “€ 20,003.57”
> “In addition, the active ingredient sorafenib can be prescribed for off-label use since August 2024 for the treatment of adults with progressing desmoid tumours who have demonstrated disease progression and require treatment (see Annex VI to the Pharmaceuticals Directive).”

Source: [G-BA justification to the resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/40-1465-12520/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_TrG_EN.pdf)

<a id="topic-4.1-17"></a>

#### OGSIVEO wholesale acquisition cost, Connecticut disclosure dated January 2026

> “Connecticut HB 6669”
> “The WAC represents published catalogue or list price and may not represent actual transactional prices.”
> “82448-0100-14”
> “Oral Tablet 100 MG”
> “82448-0150-14”
> “Oral Tablet 150 MG”
> “$7,746.58”
> “Generic versions of OGSIVEO® are not currently available.”
> “01/05/2026”

Source: [SpringWorks Connecticut OGSIVEO price disclosure (2026)](https://springworkstx.com/wp-content/uploads/2024/06/CT-Price-Disclosure-Form-2024-v2.pdf)

<a id="topic-4.1-18"></a>

#### OGSIVEO wholesale acquisition cost at introduction, December 2023, superseded in January 2026

> “82448-0050-18”
> “OGSIVEO (Nirogacestat) 50mg”
> “tablets, 180-ct bottle”
> “12/4/2023”
> “WAC AT INTRODUCTION”
> “$29,000”
> “Additionally, SpringWorks assessed current market pricing for comparable orphan rare disease and oncology drugs, which included broad-based physician, payer and population health decision maker feedback.”

Source: [Vermont Attorney General new drug report (2024)](https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report%20-%2030-Day%20Report.pdf)

<a id="topic-4.1-19"></a>

#### OGSIVEO recommended dosage, dose reductions, and package size

> “The recommended dosage of OGSIVEO is 150 mg administered orally twice daily until disease progression or unacceptable toxicity.”
> “Only restart at a dosage of 100 mg twice daily after considering the potential benefit and likelihood of recurrence of the adverse reaction.”
> “Dose reductions of OGSIVEO due to an adverse reaction occurred in 42% of patients.”
> “OGSIVEO (nirogacestat) is supplied as 100 mg and 150 mg tablets.”
> “One blister card with 14 tablets”
> “82448-150-14”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-4.1-20"></a>

#### OGSIVEO U.S. net product revenue, 2023 and 2024

> “In December 2023, we began to generate revenue from sales of OGSIVEO in the United States. We record product revenue net of estimated discounts, chargebacks, rebates, product returns, and other gross-to-net revenue deductions.”
> “For the twelve months ended December 31, 2024 and December 31, 2023, we recorded net product revenue of $172.0 million and $5.4 million, respectively, from sales of OGSIVEO in the United States.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-4.1-21"></a>

#### Ogsiveo net sales after the acquisition of SpringWorks, 2025

> “The Rare Diseases franchise includes sales from the products Ogsiveo® (nirogacestat), which is used to treat progressing desmoid tumors, and Gomekli® (mirdametinib), which is the first and only medicine for both adults and children aged two years and older with NF1-associated plexiform neurofibromas (NF1-PN). Both products were gained as a result of the acquisition of SpringWorks Therapeutics, Inc., USA, (SpringWorks), on July 1, 2025, and have since contributed to our portfolio and overall growth.”
> “Net sales by major product lines/products”
> “€ million”
> “thereof: Ogsiveo® 134 2%”

Source: [Merck KGaA annual report 2025 (2026)](https://reports.emdgroup.com/en/annualreport/2025/management-report/report-on-economic-position/course-of-business-and-economic-position/healthcare.html)

<a id="topic-4.1-22"></a>

#### Ogsiveo net sales, first quarter 2026

> “Following approval in China for the treatment of tenosynovial giant cell tumor (TGCT), pimicotinib has had an encouraging start and recorded its first sales in the first quarter of 2026.”
> “Net sales mainly include Ogsiveo®, which treats progressing desmoid tumors, and Gomekli®, approved for neurofibromatosis type 1.”
> “€ million”
> “thereof: Ogsiveo® 63 3%”

Source: [Merck KGaA press release, first quarter 2026 results (2026)](https://www.emdgroup.com/en/news/q1-2026-13-05-2026.html)

<a id="topic-4.1-23"></a>

#### Ogsiveo net sales, second quarter 2026

> “Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its financial results for the second quarter of 2026.”
> “Rare Diseases, the new strategic pillar in Healthcare, contributed € 115 million to net sales.”
> “€ million”
> “thereof: Ogsiveo® 75 3 %”

Source: [Merck KGaA press release, second quarter 2026 results (2026)](https://www.emdgroup.com/en/news/q2-2026-06-08-2026.html)

<a id="topic-4.1-24"></a>

#### Ogsiveo net sales, third quarter 2026

> “In the third quarter of 2026, net sales reached € 2.3 billion, an organic increase of 0.9% year-on-year.”
> “Sales of Ogsiveo®, indicated for the treatment of progressing desmoid tumors, increased by 24.5% organically.”
> “Net sales by major product lines / products”
> “€ million”
> “thereof: Ogsiveo® 78 3% 24.5% 1.7% –% 26.1% 62 3%”

Source: [Merck KGaA press release, third quarter 2026 results (2026)](https://www.emdgroup.com/en/news/q3-2026-12-11-2026.html)

<a id="topic-4.1-25"></a>

#### U.S. incidence and actively managed population estimated by SpringWorks Therapeutics

> “The annual incidence is estimated to be 1,000 to 1,650 new desmoid tumor patients diagnosed each year in the United States.”
> “Based on market research studies with feedback from over 400 physicians who manage patients with desmoid tumors, we believe that approximately 50% of patients receiving a locoregional intervention, such as surgery, or off-label systemic therapies will not have a satisfactory treatment outcome and will require subsequent treatment for their desmoid tumors.”
> “Additionally, we believe that up to 90% or more of patients will eventually receive an active intervention.”
> “Based on this market research, we estimate that, in any given year over the next decade, approximately 5,500 to 7,000 desmoid tumor patients will be actively managed in the United States.”
> “More recent analyses, including a review of International Classification of Diseases, Tenth Edition, or ICD-10, claims data between the introduction of desmoid tumor-specific ICD-10 codes in October 2023 and October 2024, reveals that there are approximately 11,000 desmoid tumor patients receiving physician care annually in the United States.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-4.1-26"></a>

#### U.S. actively managed population, treatment duration, and sarcoma centers estimated by Immunome

> “10-11k Actively Managed Patients (US) 1”
> “~85 Sarcoma Centers-of-Excellence4”
> “~50% of patients have desmoid tumors for more than 5 years2”
> “1) Immunome Analysis 2) K Mercier et al. ESMO Sarcoma 2024 Poster 3) Immunome Primary Market Research 4) Immunome Analysis”
> “Patients may receive ~1.5–2 years of treatment, pause, and return for treatment3”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-4.1-27"></a>

#### Immunome expectation of gamma secretase inhibitor market share

> “The uptake of OGSIVEO® in the United States in the treatment of desmoid tumors demonstrates the potential for GSIs to address unmet need, and we believe that GSIs may ultimately capture much of the market for desmoid tumor therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-4.1-28"></a>

#### Immunome expectations for payer coverage, pricing, and launch sites

> “US & EMA orphan designation has favorable pricing implications”
> “Launch focused on 85 sarcoma centers of excellence expected to drive efficiency and quick uptake”
> “>90% anticipated payer coverage”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-4.1-29"></a>

#### Quality-adjusted time without symptoms or toxicity analysis of nirogacestat in DeFi, ISPOR Europe 2025

> “Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe; November 9–12, 2025; Glasgow, Scotland”
> “This presentation was supported by SpringWorks Therapeutics, Inc.”
> “TB is an employee of SpringWorks Therapeutics, Inc.”
> “Each health state was weighted with fixed utility values (UTWiST=1.0, UTOX=0.5, UREL=0.5), consistent with prior Q-TWiST literature, to evaluate trade-off between treatment-related toxicity and survival outcomes”
> “The analysis utilized the double-blind phase of the DeFi trial to maintain randomization and minimize confounding”
> “Outcomes were assessed over 20.6 months, which corresponds to the median treatment duration for nirogacestat”
> “The model provided the option to include background mortality that was adjusted for the disease using a standardized mortality ratio of 3.70.”
> “The estimated 5-year overall survival (OS) for patients is 96%”
> “Patients treated with nirogacestat had statistically significant and superior Q-TWiST gain of 71.60 days (P<.001) and a clinically important relative gain of 11.52% versus placebo”
> “This analysis did not include patient-reported utility data, preventing insight into real-world quality of life”

Source: [Malaviya et al. (2025)](https://springworkstx.com/wp-content/uploads/2025/11/Malaviya_ISPOR-EU_2025_Q-TWiST_POS.pdf)

<a id="topic-4.1-30"></a>

#### Cost per outcome of sorafenib at Medicare Part D prices

> “Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day).”
> “At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697.”
> “When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year.”
> “For the treatment of desmoid tumors, Sorafenib led to improved PFS, but at a significant cost per patient.”

Source: [Johns et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35112974/)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
